Clinova – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 5 PAGES: 20

Clinova – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Clinova - Product Pipeline Review - H2 2011” provides data on the Clinova’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Clinova’s corporate website, SEC filings, investor presentations and featured press releases, both from Clinova and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Clinova - Brief Clinova overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Clinova human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Clinova with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Clinova’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Clinova’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Clinova in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Clinova’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Clin

More Info
									Clinova – Product Pipeline Review




                Clinova – Product Pipeline Review – H2 2011


                                                                                              Reference Code: GMDHC02131CDB

                                                                                                   Publication Date: DEC 2011




Clinova – Product Pipeline Review – H2 2011
                                                                                          GMDHC02131CDB / Published DEC 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Clinova – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 3
Clinova Snapshot ............................................................................................................................................................................... 4
    Clinova Overview........................................................................................................................................................................... 4
    Key Information ............................................................................................................................................................................. 4
    Key Facts....................................................................................................................................................................................... 4
Clinova – Research and Development Overview ............................................................................................................................... 5
    Key Therapeutic Areas .................................................................................................................................................................. 5
Clinova – Pipeline Review .................................................................................................................................................................. 7
    Pipeline Products by Stage of Development ................................................................................................................................. 7
    Pipeline Products – Monotherapy ................................................................................................................................................. 8
Clinova – Pipeline Products Glance ................................................................................................................................................... 9
    Clinova – Late Stage Pipeline........................................................................................................................................................ 9
         Phase III Products/Combination Treatment Modalities ............................................................................................................. 9
    Clinova – Early Stage Pipeline Products ..................................................................................................................................... 10
         Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 10
Clinova – Drug Profiles ..................................................................................................................................................................... 11
    CLIN 3004 ................................................................................................................................................................................... 11
         Product Description................................................................................................................................................................. 11
         Mechanism of Action ............................................................................................................................................................... 11
         R&D Progress ......................................................................................................................................................................... 11
    CLIN 3007 ................................................................................................................................................................................... 12
         Product Description................................................................................................................................................................. 12
         Mechanism of Action ............................................................................................................................................................... 12
         R&D Progress ......................................................................................................................................................................... 12
    CLIN 3010 ................................................................................................................................................................................... 13
         Product Description................................................................................................................................................................. 13
         Mechanism of Action ............................................................................................................................................................... 13
         R&D Progress ......................................................................................................................................................................... 13
    CLIN 3011 ................................................................................................................................................................................... 14
         Product Description................................................................................................................................................................. 14
         Mechanism of Action ........
								
To top